• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Does New Kidney Test Data Change The Bull Case For CareDx Stock (CDNA)?

    Simply Wall St·10/24/2026 11:30:42
    Listen to the news
    • CareDx highlighted new clinical data at ASN Kidney Week 2026 in Denver showing that its AlloSure Kidney dd-cfDNA test helped assess graft injury, interpret ambiguous biopsies and reduce reliance on invasive surveillance biopsies in kidney transplant patients.
    • An AlloSure Kidney level of 1% or higher was linked to a nearly 3x higher risk of allograft loss or major kidney function decline, which directly ties the test to clinically meaningful outcomes in transplant care.
    • This article examines how CareDx's investment narrative is influenced by AlloSure Kidney's risk stratification data in real transplant practice.
    Spot under-the-radar peers tackling complex diagnostics like CareDx by scanning our hand picked 34 healthcare AI stocks, which are pushing testing and decision support deeper into everyday clinical practice.

    CareDx Investment Narrative Recap

    To hold CareDx, you need to believe transplant clinicians keep using molecular tests like AlloSure Kidney as a routine decision tool, and that payer coverage and reimbursement remain supportive enough for that usage to matter. The new AlloSure data strengthens the clinical story, yet the biggest near term swing factor still looks like how draft LCD policies on bundled payments and test frequency ultimately land.

    The main operational risk does not change much after this update. CareDx remains heavily exposed to reimbursement terms for a small group of products, while also working through CFO transition and execution items like EPIC integration. Strong evidence is helpful, but it does not directly resolve pricing, coding, or coverage questions.

    The AlloSure Kidney dataset that ties a 1% or higher dd cfDNA reading to a nearly 3x higher risk of graft loss or major function decline feels most relevant for the next clinical adoption leg. It links a lab value to outcomes clinicians care about, which often matters for guideline discussions and payer assessments of medical necessity.

    For catalysts, investors are watching whether CareDx can convert this type of evidence into durable ordering patterns, broader protocol inclusion, and stable reimbursement under evolving value based frameworks. The flip side is clear: if bundled payments or frequency caps tighten despite stronger data, the operational leverage that comes from growing testing volumes could be limited.

    CareDx's narrative projects US$659.6 million revenue and US$57.5 million earnings by 2029. This assumes 12.9% yearly revenue growth and an earnings decline of US$53.5 million from the US$111.0 million reported today.

    Uncover why CareDx's fair value indicates a 7% potential downside to its current price, which leaves little room for error.

    NasdaqGM:CDNA 1-Year Stock Price Chart
    NasdaqGM:CDNA 1-Year Stock Price Chart

    Exploring Other Perspectives

    You might read this AlloSure Kidney update and immediately think about upside. The most optimistic CareDx analysts were already modeling about 13.5% annual revenue growth and roughly US$669.7 million in sales by 2029. That group sees oncology tests like NavDx as the real swing factor, so fresh transplant data could eventually pull their narrative even further apart from the more cautious earnings view near US$28.6 million. Use that spread as a reminder that opinions range widely, and explore which version of the story fits your own expectations.

    Explore 3 other CareDx fair value estimates, including one that suggests as much as 44% potential upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond CareDx?

    If the CareDx story has sharpened how you think about risk, return and clinical proof, use that same lens to scan a broader watchlist. The Simply Wall St screener can help you quickly surface other businesses that fit the kind of balance between quality, resilience and upside that you want to back.